Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arcus Biosciences : Announces New Employment Inducement Grants

08/24/2021 | 04:11pm EST

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted twelve new employees options to purchase a total of 104,200 shares of the Company’s common stock at an exercise price per share of $29.35, which was the closing price on August 23, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has five molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, and non-small cell lung. Quemliclustat (AB680), the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development in combination with zimberelimab and gemcitabine/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study evaluating zimberelimab monotherapy, domvanalimab plus zimberelimab and domvanalimab plus etrumadenant plus zimberelimab for first-line treatment of PD-L1 ≥ 50% metastatic non-small cell lung cancer (NSCLC). In addition, domvanalimab has advanced into ARC-10, Arcus’s “two in one trial” to support the potential approvals of both zimberelimab and zimberelimab plus domvanalimab and is expected to advance into a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage 3 NSCLC setting later this year. AB308, an anti-TIGIT antibody that is FcR-enabled, is in clinical development, with a potential focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences


ę Business Wire 2021
All news about ARCUS BIOSCIENCES, INC.
11/24Arcus Biosciences Announces New Employment Inducement Grants
BU
11/22Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conferenc..
BU
11/19Berenberg Bank Adjusts Arcus Biosciences' Price Target to $68 From $60, Maintains Buy R..
MT
11/19Citigroup Adjusts Price Target on Arcus Biosciences to $53 From $42, Reiterates Buy Rat..
MT
11/19Barclays Adjusts Price Target on Arcus Biosciences to $60 From $48, Keeps Overweight Ra..
MT
11/19Wedbush Lifts Price Target on Arcus Biosciences to $67 From $52 After Gilead Opts In to..
MT
11/18Health Care Stocks Ending Little Changed in Quiet Trading
MT
11/18Arcus Biosciences Shares Rally as Gilead Exercises Options
DJ
11/18Gilead Exercises Option to Co-Develop Three Arcus Biosciences Clinical-Stage Cancer Pro..
MT
11/18SVB Leerink Adjusts Price Target on Arcus Biosciences to $100 From $68, Maintains Outpe..
MT
More news
Analyst Recommendations on ARCUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 169 M - -
Net income 2021 -248 M - -
Net cash 2021 1 053 M - -
P/E ratio 2021 -12,8x
Yield 2021 -
Capitalization 3 257 M 3 257 M -
EV / Sales 2021 13,0x
EV / Sales 2022 11,6x
Nbr of Employees 236
Free-Float 62,7%
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 46,36 $
Average target price 64,60 $
Spread / Average Target 39,3%
EPS Revisions
Managers and Directors
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Kartik Krishnan Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ARCUS BIOSCIENCES, INC.78.58%3 257
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431